Nicola Pietrafusa, Alessandro Ferretti, Marina Trivisano, Luca de Palma, Costanza Calabrese, Giusy Carfì Pavia, Ilaria Tondo, Simona Cappelletti, Federico Vigevano, Nicola Specchio
BACKGROUND: A pharmaceutical grade formulation of cannabidiol (CBD) has been approved for the treatment of Dravet syndrome and Lennox-Gastaut syndrome; however, this formulation is not yet available to patients outside the USA. In addition, CBD is thought to have broad anti-seizure properties that may be beneficial for other types of intractable epilepsy. OBJECTIVE: The aim of this study was to evaluate the efficacy, safety and tolerability of artisanal medical CBD oil in patients with developmental and epileptic encephalopathy (DEE) at the tertiary epilepsy center of Bambino Gesù Children's Hospital in Rome, Italy...
August 2019: Paediatric Drugs